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Case Presentation: We describe the presentation to the emergency department of a patient with 
recurrent ovarian cancer treated with bevacizumab with the complication of bowel perforation. 
Discussion: We review the frequency and outcomes of bevacizumab-related bowel perforation. We also 
report the patient’s imaging findings, including the radiologic presentation of free intraperitoneal air and 
portal venous gas, both indicative of bowel perforation and the need for emergent surgical evaluation. 
Our case also illustrates the potentially catastrophic side effects of bevacizumab and other targeted 
oncologic therapies of which emergecny physicians may not be aware. [Clin Pract Cases Emerg 
Med.2020;4(2):XX–XX.]
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CASE PRESENTATION
A 69-year-old, African-American female with recurrent 
stage IIIC ovarian carcinoma treated with bevacizumab 
presented to the emergency department (ED) with 
abdominal pain, distention, vomiting, and hypotension. 
After initial stabilization, an upright abdominal radiograph 
(Image 1) revealed peritoneal free air and portal venous gas 
concerning for bowel perforation, which was confirmed by 
computed tomography (CT) of the abdomen and pelvis 
(Images 2 and 3). 
The patient was admitted to the gynecology oncology 
service and maintained on crystalloids and antibiotics. She 
had minimal symptoms. In accordance with her wishes, no 
further aggressive intervention was pursued, and she died 
on hospital day three.
DISCUSSION
Bevacizumab is a monoclonal antibody targeting the 
vascular endothelial growth factor receptor used in multiple 
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Image 1. Upright abdominal radiograph revealing free air along the 
lateral margin of the liver (arrows) and branching gas in the liver 
(triangles), concerning for portal venous gas.
cancer types, including ovarian.1, 2 Complications include 
bowel perforation and gastrointestinal (GI) bleeding.3 The 
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What do we already know about this 
clinical entity? 
Bevacizumab is an increasingly used 
targeted chemotherapeutic agent 
with infrequent, severe complications 
including gastrointestinal perforation.
What is the major impact of the image(s)?
Severe ischemic bowel related to 
bevacizumab therapy and widespread 
diagnostic findings of mesenteric 
ischemia, portal venous gas, and free air 
are demonstrated.
How might this improve emergency 
medicine practice?  
Early recognition and diagnosis for bowel 
perforation in patients on bevacizumab is 
essential to allow prompt surgical evaluation 
and therapy.
incidence of bowel perforation in ovarian cancer treated 
with bevacizumab is estimated to be 2-3%,4 with a relative 
risk of 2.57 compared to ovarian cancer alone.5 Bowel 
perforation and other severe GI pathologies are seen with 
other commonly-used targeted therapies such as sunitinib, 
sorafenib, everolimus, and temsirolimus.6 This patient had 
Image 3. Computed tomography of the abdomen revealing 
intraperitoneal free air (arrows), bowel wall pneumatosis 
(triangles), and air in the mesenteric vasculature (*).
Image 2. Computed tomography scan of the abdomen revealing 
extensive ascites (*), intraperitoneal free air (arrows), and extensive 
branching portal venous gas (triangles), indicative of bowel 
ischemia, necrosis, and perforation.
other independent risk factors for perforation including 
bowel resection-reanastamosis, peritoneal carcinomatosis, 
and partial small bowel obstructions.
Bowel perforation secondary to bevacizumab has an 
estimated 60-day mortality of 25%.2 The diagnosis is 
confirmed by radiographs or CT of the abdomen 
demonstrating intraperitoneal free air, pneumatosis 
intestinalis, or portal venous gas. While management is 
generally surgical, supportive care, including antibiotics, 
parenteral nutrition, and fluid resuscitation, has been 
successful in poor surgical candidates. 
In summary, we report a case of bowel perforation 
related to bevacizumab therapy. This case demonstrates the 
potentially life-threatening side effects of bevacizumab and 
other frequently-used, targeted therapies requiring ED 
diagnosis and resuscitation, and the complex imaging 
findings associated with the diagnosis of bowel perforation 
in a patient with recurrent ovarian cancer.
The documented Institutional Review Board Policy has been 
obtained and filed for publication of this case report.
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